Abstract: The disclosure provides Fc?RIIA-binding molecules, for example, humanized monoclonal antibodies capable of inhibiting Fc?RIIA activity, and methods of using the Fc?RIIA binding molecules, for example, in treating or preventing inflammatory, immune-mediated, or autoimmune diseases or disorders.
Type:
Grant
Filed:
April 28, 2017
Date of Patent:
April 19, 2022
Assignee:
Viela Bio, Inc.
Inventors:
Katherine Ann Vousden, Bo Chen, Gary Patrick Sims
Abstract: The present application provides a modified Brucella strain, its use as a medicament, and its use as a medicament for the treatment and/or prevention of brucellosis. The Brucella strain has been modified through an inactivation of the wzm gene. Further, the present application provides a pharmaceutical composition which comprises the modified Brucella strain, its use as a medicament, and its use as a medicament for the treatment and/or prevention of brucellosis. The present application also provides a kit which comprises the modified Brucella strain and a pharmaceutically acceptable carrier or diluent and its use for the treatment and/or prevention of brucellosis.
Type:
Grant
Filed:
November 26, 2018
Date of Patent:
April 12, 2022
Assignees:
CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC), UNIVERSIDAD PÚBLICA DE NAVARRA
Inventors:
María Jesús Grilló Dolset, Beatriz San Román Aberasturi, Leyre Palacios Chaves, Sara Mena Bueno, Ana Zabalza Baranguá
Abstract: The invention features engineered probiotic lacto acid bacteria (LAB) expressing a chimeric Clostridium difficile/Lactobacillus acidophilus SlpA, or fragment thereof, and its use for the treatment or prevention of Clostridium difficile infection and gut colonization.
Type:
Grant
Filed:
September 25, 2018
Date of Patent:
April 12, 2022
Assignee:
Arizona Board of Regents on Behalf of the University of Arizona
Abstract: Disclosed herein is an attenuated Acinetobacter baumannii comprising an expression vector comprising a nucleic acid encoding the ABUW_1645 protein or a variant thereof. Disclosed herein are methods of treating or preventing colonization, infection, or disease by an Acinetobacter baumannii microbe, the method comprising administering a clinically effective dose of the attenuated Acinetobacter baumannii to a subject in need thereof, wherein the attenuated Acinetobacter baumannii comprises an expression vector expressing the ABUW_1645 protein or variants thereof.
Type:
Grant
Filed:
September 19, 2018
Date of Patent:
April 5, 2022
Assignee:
THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
Inventors:
Philip Rather, David Weiss, Chui-Yoke Chin, Kyle Tipton
Abstract: Provided is an immunogenic composition including a peptide, wherein consecutive amino acids of the peptide include at least amino acids 186-193 of SEQ ID NO:1 and one or more adjuvants. In an example, the peptide is covalently linked to an amino acid sequence including SEQ ID NO:2. Also provided is a method of vaccinating a subject against Borrelia burgdorferi, including administering to the subject an effective amount of the immunogenic composition.
Abstract: This disclosure describes modified photosynthetic microorganisms, including Cyanobacteria, that have a reduced amount of a light harvesting protein (LHP) and contain one or more introduced or overexpressed polynucleotides encoding one or more enzymes associated with lipid biosynthesis, and which are capable of producing increased amounts of fatty acids and/or synthesizing triglycerides.
Type:
Grant
Filed:
August 21, 2020
Date of Patent:
March 22, 2022
Assignee:
LUMEN BIOSCIENCE, INC.
Inventors:
James Roberts, Michael Carleton, Damian Carrieri, Jason W. Hickman
Abstract: The present invention broadly provides different compositions, kits, vectors, and methods including monoclonal antibodies directed to epitopes found within lipoarabinomannan (LAM) and phosphatidyl-myo-inositol mannoside 6 (PIM6) for the diagnosis and treatment of Mycobacterium tuberculosis infections.
Type:
Grant
Filed:
June 24, 2020
Date of Patent:
March 15, 2022
Assignee:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Abstract: Provided are therapeutic compositions containing microbial populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
March 8, 2022
Assignee:
Seres Therapeutics, Inc.
Inventors:
Matthew R. Henn, Kevin Daniel Litcofsky, Anthony Mario D'Onofrio, Toshiro K. Ohsumi, Mary-Jane Lombardo McKenzie, Geoffrey von Maltzahn, David N. Cook, David Arthur Berry, Noubar B. Afeyan, John Grant Aunins
Abstract: Disclosed herein is a Chlamydia-activated B cell (CAB) platform. Also disclosed is a method of enhancing a population of B cells, comprising exposing said B cells to Chlamydia spp. under conditions suitable to enhance the population of B cells, such that expansion and differentiation of said B cells takes place, and said B cells are exposed or crosslinked to an antigen. Also disclosed are methods of producing said CABs, and treating a subject in need thereof with said CABs.
Abstract: A composition includes cells of Lactobacillus paracasei MCC1849 (NITE BP-01633). The composition is in the form of a pharmaceutical composition, a food, a drink, or a feed. The pharmaceutical composition can be used for treating an inflammatory disease, ulcer, food allergies, bronchial asthma, urticaria, pollinosis, anaphylactic shock or an opportunistic infection.
Abstract: Monoclonal antibodies (MAbs) targeting one or more specific epitopes of aspartyl (asparaginyl) ?-hydroxylase (ASPH), including humanized, bi-specific, and other chimeric MAb variants, and fragments thereof (collectively ASPH epitope-specific MAbs, or simply ASPH MAbs), are disclosed. Methods of production, purification, and use of the ASPH epitope-specific MAbs, and compositions comprising them, as agents in therapeutic and diagnostic applications to interact with target molecules in cell-free samples, cell- and tissue-based assays, animal models, and in a subject are also disclosed. Other aspects of the invention relate to use of the molecules disclosed herein to diagnose, ameliorate, or treat cell proliferation disorders and related diseases.
Abstract: The present invention provides isolated polypeptides isolatable from a Fusobacterium spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides.
Type:
Grant
Filed:
November 9, 2016
Date of Patent:
February 1, 2022
Assignee:
Epitopix, LLC
Inventors:
Charles Nelson Carver, III, Daryll A. Emery
Abstract: A method of immunizing a susceptible host against a pathogen comprising administering to the host a vaccine that comprises an attenuated recombinant live vaccine strain lacking a polynucleotide encoding CapB (LVS ?capB), wherein the LVS ?capB expresses an antigen of at least one pathogen from Table 1; or administering to the host a vaccine that comprises an attenuated Listeria monocytogenes expressing the antigen of the pathogen from Table 1; or administering to the host a prime vaccine and a heterologous booster vaccine where the prime vaccine comprises an attenuated recombinant live vaccine strain lacking a polynucleotide encoding CapB (LVS ?capB), wherein the LVS ?capB expresses an antigen of at least one pathogen from Table 1 and the heterologous booster vaccine comprises an attenuated Listeria monocytogenes expressing the antigen of the pathogen from Table 1.
Type:
Grant
Filed:
July 31, 2017
Date of Patent:
January 18, 2022
Assignee:
The Regents of the University of California
Abstract: A composition and method for activating probiotic spores in food and beverage products, such as steeped teas, coffee, soups, and sauces. A nutrient-germinant composition comprises one or more L-amino acids, optionally one or more buffers to maintain the pH of the composition when added to water in a range of around 6-8, optionally D-glucose, D-fructose, or both D-glucose and D-fructose, and optionally, an osmoprotectant. The nutrient-germinant composition, one or more species of Bacillus spores, and a food or beverage product may be pre-mixed in any combination. Water is added to the mixture and heated to a temperature range of 42 to 100° C. to germinate the probiotic spores prior to being consumed.
Type:
Grant
Filed:
March 19, 2020
Date of Patent:
December 28, 2021
Assignee:
NCH Corporation
Inventors:
Jordan E. Church, Gabriel F. K. Everett, Charles J. Greenwald, Lester Levy, Judy Pruitt, Amanda Rosmarin, Daniel Aberle, George Aboagye
Abstract: The present invention is a DNA expression vector comprising: a toxP; a mutant toxO that blocks Fe-mediated regulation of gene expression; and a DNA sequence encoding a protein, wherein the toxP and the mutant toxO regulate expression of the DNA segment encoding the protein. It is preferred that DNA expression vectors of the present invention include DNA sequences encoding a signal peptide so that a protein expressed is attached to the signal peptide prior to processing. Novel proteins are produced off of the DNA expression vector of the present invention.
Type:
Grant
Filed:
September 11, 2017
Date of Patent:
December 21, 2021
Assignees:
The Johns Hopkins University, Trustees of Boston University
Inventors:
William R. Bishai, John R. Murphy, Laurene Cheung, Shashank Gupta, Cynthia K. Bullen
Abstract: The present invention relates to particles, particularly virus-like particles (VLPs), comprising fusion polypeptides comprising selected repeat units derived from the repeating regions of Type I and Type II circumsporozoite proteins (CSP) of Plasmodium vivax (Pv), together with an amino acid sequence derived from the C-terminal PvCSP sequence. In some embodiments, the fusion polypeptide additionally comprises an amino acid sequence derived from the N-terminal PvCSP sequence and/or a surface antigen polypeptide derived from Hepatitis B virus (HBV-S). The invention also relates to nucleotide sequences coding for such fusion polypeptides, vectors and plasmids comprising such nucleotide sequences, and host cells comprising such vectors and plasmids. The invention additionally relates to compositions, particularly vaccine compositions, comprising the fusion polypeptides or VLPs for use as vaccines for the prevention of malaria.
Abstract: The disclosure relates to attenuated bacterial cells expressing glycans and glycoconjugate antigens and their use in the manufacture of whole cell vaccines effective at preventing or treating bacterial infections in non-human species.
Type:
Grant
Filed:
March 14, 2018
Date of Patent:
November 23, 2021
Assignee:
London School of Hygiene and Tropical Medicine
Inventors:
Jon Cuccui, Brendan Wren, Alexandra Faulds-Pain